HK1247923A1 - 可用作哺乳動物酪氨酸激酶ror1活性抑制劑的2-苯基-3h-咪唑並[4，5-b]吡啶衍生物 - Google Patents
可用作哺乳動物酪氨酸激酶ror1活性抑制劑的2-苯基-3h-咪唑並[4，5-b]吡啶衍生物 Download PDFInfo
- Publication number
- HK1247923A1 HK1247923A1 HK18107404.5A HK18107404A HK1247923A1 HK 1247923 A1 HK1247923 A1 HK 1247923A1 HK 18107404 A HK18107404 A HK 18107404A HK 1247923 A1 HK1247923 A1 HK 1247923A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tyrosine kinase
- imidazo
- inhibitors
- phenyl
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153394 | 2015-02-02 | ||
| EP15153394 | 2015-02-02 | ||
| PCT/EP2016/052091 WO2016124553A1 (en) | 2015-02-02 | 2016-02-01 | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1247923A1 true HK1247923A1 (zh) | 2018-10-05 |
Family
ID=52449976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18107404.5A HK1247923A1 (zh) | 2015-02-02 | 2016-02-01 | 可用作哺乳動物酪氨酸激酶ror1活性抑制劑的2-苯基-3h-咪唑並[4，5-b]吡啶衍生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10550113B2 (zh) |
| EP (1) | EP3253754B1 (zh) |
| JP (1) | JP6629884B2 (zh) |
| KR (1) | KR102493943B1 (zh) |
| CN (1) | CN107567445B (zh) |
| AU (1) | AU2016214492B2 (zh) |
| BR (1) | BR112017016428B1 (zh) |
| CA (1) | CA2973773C (zh) |
| ES (1) | ES2875737T3 (zh) |
| HK (1) | HK1247923A1 (zh) |
| IL (1) | IL253380B (zh) |
| MX (1) | MX374552B (zh) |
| WO (1) | WO2016124553A1 (zh) |
| ZA (1) | ZA201705933B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660303B2 (en) | 2016-07-11 | 2023-05-30 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
| US11008318B2 (en) | 2016-07-11 | 2021-05-18 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| JP7378267B2 (ja) | 2018-11-12 | 2023-11-13 | 東ソー株式会社 | コバルト錯体、その製造方法、及びコバルト含有薄膜の製造方法 |
| WO2020160197A1 (en) | 2019-01-29 | 2020-08-06 | The Regents Of The University Of California | Novel treatments of glaucoma |
| WO2021057696A1 (zh) * | 2019-09-27 | 2021-04-01 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
| CN117049977A (zh) * | 2023-08-16 | 2023-11-14 | 四川伊诺达博医药科技有限公司 | 一种n-乙基-2-(4-甲酰基苯基)乙酰胺的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1460067A4 (en) | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| SE0202464D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Use of compounds |
| JP2008521768A (ja) | 2004-12-23 | 2008-06-26 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用 |
| WO2006066913A2 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| EP1861387B1 (en) | 2005-01-28 | 2014-04-16 | Daewoong Pharmaceutical Co., Ltd. | Benzimidazole derivatives and pharmaceutical compositions thereof |
| WO2006125958A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EP1963315B1 (en) | 2005-12-22 | 2014-10-08 | Cancer Research Technology Limited | Enzyme inhibitors |
| CA2637392A1 (en) | 2006-01-23 | 2007-07-26 | Crystalgenomics, Inc. | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
| WO2008121064A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705 |
| RU2009135616A (ru) | 2007-03-30 | 2011-05-10 | Астразенека Аб (Se) | НОВЫЕ АМИДАЗО[4,5-b]ПИРИДИН-7-КАРБОКСАМИДЫ 704 |
| WO2009001021A1 (en) | 2007-06-26 | 2008-12-31 | Chroma Therapeutics Ltd. | Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases |
| JP2011513329A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体 |
| WO2011066211A1 (en) | 2009-11-24 | 2011-06-03 | Glaxosmithkline Llc | Azabenzimidazoles as fatty acid synthase inhibitors |
| DK2513146T3 (en) | 2009-12-18 | 2017-07-31 | Kancera Ab | Antibodies against ROR1 capable of inducing cell death by CLL |
| EP2809671B1 (en) * | 2012-01-30 | 2016-01-13 | Cephalon, Inc. | Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders |
-
2016
- 2016-02-01 EP EP16702147.6A patent/EP3253754B1/en active Active
- 2016-02-01 US US15/545,523 patent/US10550113B2/en active Active
- 2016-02-01 AU AU2016214492A patent/AU2016214492B2/en not_active Ceased
- 2016-02-01 WO PCT/EP2016/052091 patent/WO2016124553A1/en active Application Filing
- 2016-02-01 CN CN201680008251.1A patent/CN107567445B/zh not_active Expired - Fee Related
- 2016-02-01 HK HK18107404.5A patent/HK1247923A1/zh unknown
- 2016-02-01 ES ES16702147T patent/ES2875737T3/es active Active
- 2016-02-01 KR KR1020177024661A patent/KR102493943B1/ko active Active
- 2016-02-01 MX MX2017009600A patent/MX374552B/es active IP Right Grant
- 2016-02-01 BR BR112017016428-0A patent/BR112017016428B1/pt not_active IP Right Cessation
- 2016-02-01 CA CA2973773A patent/CA2973773C/en active Active
- 2016-02-01 JP JP2017558782A patent/JP6629884B2/ja active Active
-
2017
- 2017-07-10 IL IL253380A patent/IL253380B/en unknown
- 2017-08-31 ZA ZA2017/05933A patent/ZA201705933B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180002329A1 (en) | 2018-01-04 |
| BR112017016428A2 (pt) | 2018-04-10 |
| CN107567445A (zh) | 2018-01-09 |
| ES2875737T3 (es) | 2021-11-11 |
| US10550113B2 (en) | 2020-02-04 |
| JP2018507255A (ja) | 2018-03-15 |
| EP3253754A1 (en) | 2017-12-13 |
| KR102493943B1 (ko) | 2023-01-31 |
| MX374552B (es) | 2025-03-06 |
| BR112017016428B1 (pt) | 2023-10-24 |
| MX2017009600A (es) | 2017-11-22 |
| JP6629884B2 (ja) | 2020-01-15 |
| CA2973773C (en) | 2023-10-17 |
| IL253380A0 (en) | 2017-09-28 |
| KR20170113629A (ko) | 2017-10-12 |
| IL253380B (en) | 2021-07-29 |
| ZA201705933B (en) | 2018-12-19 |
| CN107567445B (zh) | 2021-06-29 |
| CA2973773A1 (en) | 2016-08-11 |
| AU2016214492B2 (en) | 2020-05-07 |
| AU2016214492A1 (en) | 2017-08-24 |
| WO2016124553A1 (en) | 2016-08-11 |
| EP3253754B1 (en) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247923A1 (zh) | 可用作哺乳動物酪氨酸激酶ror1活性抑制劑的2-苯基-3h-咪唑並[4，5-b]吡啶衍生物 | |
| PH12019500776A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| MX2021011435A (es) | Inhibidores de hpk1 y metodos de uso de los mismos. | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| WO2017108723A3 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| MX373658B (es) | Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2-il)amino-benzoico como inhibidor de quinasa p38. | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| HK1246286A1 (zh) | Lrrk2抑制劑及其製備和使用方法 | |
| WO2011149950A3 (en) | Bicyclic heteroaryl kinase inhibitors and methods of use | |
| PH12013501758A1 (en) | Pyrazolo [1,5-a] pyridines as trk inhibitors | |
| EP3877371A4 (en) | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES | |
| EP4442318A3 (en) | Heterocyclic inhibitors of mct4 | |
| SA519400792B1 (ar) | مشتقات إيميدازو [1،2-a] بيريدين، طرق لتحضيرهم واستخدامهم | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| EA201890821A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
| ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| WO2015114638A3 (en) | Use of casein kinase i inhibitors for depleting stem cells | |
| HK1248601A1 (zh) | 作為激酶抑制劑的嘧啶衍生物及其治療應用 | |
| HK1249907A1 (zh) | 作為氨基脲敏感性胺氧化酶(ssao)酶抑制劑的結晶化合物 | |
| WO2014038881A3 (ko) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 |